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BACKGROUND: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen.
METHODS: We report the outcome for a consecutive series of chemonaive patients with metastatic or locally advanced
neuroendocrine tumours treated with a combination of 5-fluorouracil (500mgm
 2), cisplatin (70mgm
 2) and streptozocin
(1000mgm
 2) (FCiSt) administered three weekly for up to six cycles. Patients were assessed for radiological response, toxicity and
survival.
RESULTS: In the 79 patients assessable for response, treatment with FCiSt was associated with an overall response rate of 33% (38% for
pancreatic primary sites and 25% for non-pancreatic primary sites). Stable disease occurred in a further 51%, with progression in 16%.
The median time to progression was 9.1 months and median overall survival was 31.5 months. The most common grade 3–4 toxicity
was neutropaenia (28% patients) but grade 3–4 infection was rare (7%). The most frequent non-haematological grade 3–4 toxicity
was nausea and vomiting (17%). Prognostic factors included Ki-67, mitotic index, grade and chromogranin A, whereas response to
chemotherapy was predicted by mitotic index, grade and a-fetoprotein.
CONCLUSION: FCiSt is an effective regimen for neuroendocrine tumours with an acceptable toxicity profile. Grade and mitotic index
are the best predictors of response.
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Neuroendocrine tumours (NETs) are a heterogeneous group of
malignancies that arise from various sites in the body, most
commonly the gastrointestinal (GI) tract. The clinical course varies
from a highly aggressive disease with a median survival of around
6 months in patients with metastatic high-grade tumours, to a
more indolent process in which patients live with their disease for
up to 20 years (Pape et al, 2008a,b; Yao et al, 2008). Recent data
suggest that the incidence of NETs has increased fivefold over
the past 30 years and is now 5.25 per 100000. Moreover the
long survival times mean that the prevalence of NETs is now
greater than that of other GI tumours including pancreatic and
oesophagogastric cancers (Yao et al, 2008).
Surgery is the only curative intervention, but in the majority of
cases metastasis has already occurred at the time of presentation
and palliative measures are required. For functional tumours,
hormone-related symptoms can be controlled with somatostatin
analogues, although whether somatostatin analogues influence
tumour growth is not clear. Loco-regional interventions including
embolisation, ablation or debulking surgery have also been used to
ameliorate symptoms associated with hormone production.
A variety of systemic chemotherapy regimens have been
explored (Toumpanakis et al, 2007) but there is no accepted
standard of care. The initial studies by Moertel et al (1980, 1992)
using streptozocin in combination with fluorouracil or doxorubi-
cin in pancreatic NETs gave encouraging response rates of over
60% based on reduction of hepatomegaly and biochemical
response. However subsequent studies applying more rigorous
objective response criteria report response rates between 6 and
45% for pancreatic NETs (Eriksson et al, 1990; Cheng and Saltz,
1999; Kouvaraki et al, 2004) and 15–30% for non-pancreatic NETs
(Engstrom et al, 1984; Bukowski et al, 1987; Sun et al, 2005). The
combination of cisplatin and etoposide has also been evaluated,
and high response rates have been reported for poorly differen-
tiated tumours (Moertel et al, 1991; Mitry et al, 1999; Fjallskog
et al, 2001). These studies have also included a small number
of patients with well-differentiated endocrine cancers (WDECs)
who had failed previous chemotherapy and achieved response
rates ranging from 9 to 45%. However cisplatin has never been
systematically tested as first-line therapy in a large series of
WDECs.
Here we report for the first time, the clinical outcome of a
series of 82 consecutive patients with advanced NETs prospec-
tively collected over a period of 8 years, who were all treated
with the novel combination: 5-fluorouracil (500mgm
 2), cisplatin
(70mgm
 2) and streptozocin (1000mgm
 2) (FCiSt) on day 1
of a three weekly cycle. Patients were assessed for radiological
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sresponse, toxicity and survival, and prognostic and predictive
factors associated with response to chemotherapy were elucidated.
PATIENTS AND METHODS
Patients
Patients with advanced NETs treated with FCiSt chemotherapy at
the Royal Free Hospital were identified from a prospective
database. Between May 1999 and April 2008, 98 consecutive
patients were treated of which 82 were included in the analysis.
Reasons for exclusion were chemotherapy given with adjuvant
intent (n¼2), previous chemotherapy or chemoembolisation
(n¼12), no evaluable imaging or clinical follow-up (n¼2).
Patients who had undergone external beam radiotherapy earlier
were included in the study, provided that disease was measured
outside the radiation field. Patients with tumours of all primary
sites and with unknown primary tumours were included in the
analysis. Two patients received subcutaneous octreotide therapy
concurrently with chemotherapy. Indications to commence
chemotherapy were radiological progression (n¼17), tumour
grade (n¼25), progressive symptoms related to increasing tumour
burden (rather than hormone secretion) (n¼36) or intention of
downstaging the disease for surgery (n¼4).
Chemotherapy
FCiSt chemotherapy consisted in order: calcium folinate 45mg
over 2h, 5-fluorouracil 500mgm
 2 by slow bolus, streptozocin
1000mgm
 2 in 1000ml 0.9% saline (Nsaline) over 2h, mannitol
20g in 200ml Nsaline over 30min, cisplatin 70mgm
 2 in 1000ml
Nsaline over 2h followed by post-hydration. Chemotherapy was
administered every 21 days for a maximum of 6 cycles. For
patients with glomerular filtration rate (GFR), assessed by
51Cr-
EDTA clearance, less than 60mlmin
 1, either at baseline or that
developed during chemotherapy, cisplatin was substituted with
carboplatin AUC 5mgml
 1min
 1 (Calvert formula) referred to as
FCaSt. Cycles of chemotherapy were delayed until recovery
of neutrophil count X1.0 10
9 per litre and platelet count
X100 10
9 per litre. Doses of all drugs were reduced by 20%
following grade 3 non-haematological toxicity or treatment delay
due to myelosuppression. Patients who had not progressed after
three cycles of chemotherapy continued to six cycles, in the
absence of unacceptable toxicity.
Response and toxicity assessment
Baseline scans were performed within 6 weeks before starting
chemotherapy. Response was assessed by CT scan after three
cycles of chemotherapy, with patients continuing to six cycles of
chemotherapy in the absence of progression. Further response
assessment was by CT scan after completion of chemotherapy, and
at three monthly intervals until progression. Three patients were
not assessable for response after receiving two, three and six cycles
of chemotherapy respectively. Response was determined by
two independent radiologists using RECIST criteria, with best
response reported without a subsequent confirmation scan.
Time to response (TTR) was recorded as the time from the date
of commencing chemotherapy to demonstration of objective
response assessed by independent review, and duration of
response from the date of scan confirming objective response to
disease progression. Progression-free survival (PFS) was recorded
as the time from the date of commencing chemotherapy to
demonstration of objective disease progression or death. Overall
survival (OS) was recorded as the time from the date of commencing
chemotherapy to the patient’s death. Adverse effects were recorded
prospectively with each cycle of chemotherapy, and reported using
CTCAE version 3.0 (http://ctep.cancer.gov).
Pathology and tumour assessment
Patients were diagnosed as having an NET both morphologically and
immunohistochemically. Ki-67 index was assessed by an independent
pathologist using the MIB1 antibody and counting the percentage of
positive tumour cells in 2000 neoplastic cells in the area of highest
labelling, and mitotic index (MI) was reported as the number of
mitoses per 10 high-power fields (HPFs) in areas of highest mitotic
activity. Tumours were graded using the proposed grading system of
Rindi et al (2006). Briefly tumours were graded as grade 1 (low) with
MI o2 per 10 HPFs and/or Ki-67 p2%, grade 2 (intermediate)
w i t hM I2 – 2 0p e r1 0H P F sa n d / o rK i - 6 73 – 2 0 %a n dg r a d e3( h i g h )
with MI 420 per 10 HPFs and Ki-67 420%. Tumour somatostatin
receptor expression was determined by indium octreotide scintigra-
phy, urinary 5-hydroxyindoleacetic acid (5HIAA) was assessed by 24h
urine collection using standard laboratory methods, and chromo-
granin A (CGA) was measured using standard laboratory methods
a n dr e p o r t e da sa b n o r m a la t460Ul
 1. Baseline blood markers were
measured within 3 months of the start of chemotherapy.
Statistical analysis
Statistical analyses were performed using STATA version 10
(Stata Corp. LP, College Station, TX, USA). Median TTR, duration
of response, time to progression and OS were calculated using
Kaplan–Meier survival analysis.
We explored potential markers that were predictive of response in
relation to treatment, or prognostic in terms of overall or PFS. Ki-67
index and MI were initially examined as continuous data but
because they were not normally distributed (even when transformed
onto a logarithmic scale) they were divided up into approximate
tertiles and analysed as categorical variables. CGA was analysed in
two groups; above and below the upper limit of the normal (ULN)
range. Tumour markers were analysed in two groups; above and
below 1.5  ULN, which we have previously reported as a prog-
nostic cut off for a-fetoprotein (AFP) and human chorionic gonado-
tropin (HCG; Shah et al, 2008). Fisher’s exact test and w
2-test for
trend were used for predictive markers and data were reported for
all eligible patients. Cox regression analyses allowing for grade,
performance status, primary site (pancreatic or non-pancreatic) and
age at the start of chemotherapy were performed for each factor and
a hazard ratio and 99% confidence interval were calculated. 99% was
chosen to allow for examination of several factors.
RESULTS
Patient characteristics
W et r e a t e d8 2p a t i e n t sw i t ham e d i a na g eo f5 5y e a r s( r a n g e2 2 – 8 1
years) (Table 1). Primary tumour site was pancreatic in 49 patients
(60%), GI tract in 9 patients (11%), lung in 8 patients (10%), ovarian
in 1 patient and unknown in 15 patients (18%). Metastatic disease was
present in 89% of patients and the liver was the most common secon-
dary site occurring in 76%. Previous systemic treatment included
subcutaneous octreotide therapy,
131IM I B G( n¼4),
90YD O T A
octreotide radionucleotide therapy (n¼3), arterial embolisation,
interferon-a, external beam radiotherapy and 57 patients (70%) had
no prior therapy (Table 1). At least three cycles of chemotherapy were
given in 93% cases and 72% received at least six cycles. Six patients
were treated with carboplatin AUC 5 due to a low GFR at baseline
(n¼5) and poor cardiac function precluding appropriate
pre-hydration (n¼1). A further six patients were switched from
cisplatin to carboplatin because of emergent cisplatin-related toxicity.
Adverse events
Chemotherapy, in general, was well tolerated with adverse effects
detailed in Table 2. The most common toxicity was fatigue
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patients. Grade 3 or 4 side effects were uncommon, with the
highest incidence being neutropaenia (28%) although grade 3/4
infection only occurred in 7%. There was no grade 3/4 renal
toxicity and only 2% had grade 3/4 neuropathy. In contrast to
doxorubicin-containing regimens FCiSt did not cause hair loss.
There were no toxic deaths, although one patient died on
treatment due to disease progression.
Response assessment
Of the 82 patients, 79 were assessable for response. The response
rate for tumours of pancreatic origin was 38% (18 out of 47
patients) whereas that for non-pancreatic tumours was 25%
(8 out of 32 patients) (Table 3). One patient with a grade 3
bronchial NET achieved a partial response after six cycles and went
on to have his primary tumour and involved mediastinal lymph
nodes resected. On histological examination there was no viable
remaining tumour and he remains well and disease free 5 years
after resection. Overall, objective response rate was 33% (n¼26),
with stable disease as best response in 51% (n¼40), and
progressive disease in 16% (n¼13). Stable disease lasting more
than 6 months occurred in 39% (n¼31) of patients. The median
TTR was 20 weeks (range 7–47 weeks) and the median duration
of response was 36 weeks. Delayed response was observed in five
patients (19% of responding patients), with RECIST criteria for
response not being met at the end of treatment CT scan but
reached on subsequent follow-up CT scans while off treatment.
Prediction of response
We examined factors that predicted for response to chemotherapy
(Table 3). We found no statistical difference in response rates
between tumours with pancreatic primary and non-pancreatic
primary sites (38 vs 25% respectively, P¼0.24, Fisher’s exact test).
There was some evidence to suggest that histological grade
predicted response to chemotherapy, with a higher response rate
with higher histological grade (P¼0.02, w
2-test for trend). Of the
five patients with delayed response to chemotherapy one had a
high-grade tumour, three had intermediate-grade tumour and one
had low-grade tumour.
We also assessed how well proliferative fraction, assessed with
Ki-67, or MI predicted response. Overall there was a moderately
strong correlation between MI and Ki-67 (r¼0.68, Po0.0001,
Spearman’s correlation coefficient). We found the MI to be
significantly associated (P¼0.008, w
2-test for trend) with response
to chemotherapy, with response rates increasing from 15% for
MI 0–1 to 55% for MI X5.
There was some evidence to suggest that Ki-67 index may
also predict response to chemotherapy (Table 3), although the
difference in response rate between low, medium and high tertiles
did not quite reach statistical significance (P¼0.019, w
2-test
for trend). Similarly there was some evidence that poorly
differentiated tumours had a higher response rate than well-
differentiated tumours (P¼0.046).
Table 2 Toxicity according to CTCAE version 3.0
Worst toxicity grade (no of patients)
Toxicity 1 2 3 4
Nausea 23 22 10 2
Vomiting 12 15 12 2
Fatigue 25 29 6 0
Diarrhoea 12 9 6 2
Neuropathy 23 5 1 1
Stomatitis 17 7 1 0
Infection 6 8 3 3
ANC 8 19 21 2
Haemoglobin 27 16 6 0
Renal 5 5 0 0
Platelet 21 7 3 1
Abbreviation: ANC¼absolute neutrophil count.
Table 1 Clinicopathological features of patients
Primary site Pancreatic Non-pancreatic All
Number 49 33 82
Median age (range) 54.9 (24.4–81.6) 57.4 (22.2–67.7) 55.4 (22.2–81.6)
Male 27 15 42
Female 22 18 40
Performance status
0–1 44 27 71
X25 6 1 1
Site
Lung — 8 —
GI tract — 9 —
Ovarian — 1 —
Unknown — 15 —
Differentiation
Well 36 21 57
Poorly 9 9 18
Grade
Low (1) 4 4 8
Intermediate (2) 31 16 47
High (3) 5 10 15
Unknown 9 3 12
Sites of metastases
None 5 4 9
Liver 41 21 62
Lymph node 13 14 27
Lung 7 7 14
Bone 6 5 11
Other 10 6 16
Prior systemic therapy
None 33 24 57
Radionucleotide 4 3 7
Embolisation 3 0 3
Interferon 2 1 3
Octreotide 8 7 15
Radiotherapy 0 1 1
Octreotide scintigraphy
Positive 39 18 57
Negative 9 11 20
5HIAA urine
Positive 4 7 11
Negative 21 16 37
Chromogranin A
Positive (460Ul
 1)1 7 1 0 2 7
Negative (r 60Ul
 1) 9 10 19
Tumour type
Non-functional 38 31 69
Gastrinoma 5 0 5
Glucagonoma 4 1 5
Somatostatinoma 1 1 2
Vipoma 1 0 1
Abbreviations: GI¼gastrointestinal; 5HIAA¼5-hydroxyindoleacetic acid.
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AFP above 16ngml
 1 may be predictive of response (64 vs 25%
P¼0.02) whereas elevated b-HCG, CA19-9 and CGA were
uninformative.
Survival
Patients were followed up for a median of 45 months. The 1- and
2-year survival was 76.7% (95% CI 66–84.5) and 65.5% (95% CI
54.1–74.7) respectively and the median OS was 31.5 months
(Figure 1A). The 1- and 2-year PFS was 43.0% (95% CI 31.8–53.6)
and 18.3% (95% CI 10.3–28.1) and median PFS was 9.1 months
(Figure 1B). There was some evidence to suggest that performance
status (41), non-pancreatic primary and poorly differentiated
tumours (Figure 1C) may have been associated with a worse OS
whereas age was not prognostic (Table 4). Hazard ratios and 99%
CIs, adjusted for age, performance status, primary site and grade,
were calculated for each potential prognostic factor (Table 5).
A baseline CGA of 460Ul
 1 appeared to be strongly predictive
of a worse OS (Figure 1D), with the hazard ratio for patients in
the higher group reaching more than six times that of the patients
in the lower group (Table 5). Ki-67 and MI were adjusted for
performance status, age and primary site only (as tumour grade is
based on their values). There was also evidence to suggest that
both a high MI (X5) and Ki-67 (425%) were strongly associated
with poorer OS although neither quite reached statistical signi-
ficance (P¼0.017, for both; Table 5; Figures 1D and E). Elevated
a-fetoprotein, b-HCG and CA19-9 levels do not seem to be
prognostic.
DISCUSSION
In this study we report encouraging anti-tumour activity with
acceptable toxicity using a novel combination of 5-fluorouracil,
streptozocin and cisplatin for the treatment of advanced NETs.
The overall disease control rate at 6 months was 72% with a
median time to progression of 9.1 months and a median OS of
31.5 months, all of which compares favourably with previously
reported large streptozocin-based regimens (Moertel et al, 1980,
1992; Engstrom et al, 1984; Kouvaraki et al, 2004; Sun et al, 2005).
Pancreatic NETS had a higher response rate than non-pancreatic
NETs (38 vs 25%) and although this was not statistically signi-
ficant, the trend is consistent with other studies. Importantly we
found that one-fifth of responding patients had a delayed response,
achieving stable disease at their end of treatment scan but
partial response during subsequent follow-up while off treatment.
A similar observation was made by Kouvaraki et al (2004) who
reported a comparable median TTR of 4 months for fluorouracil,
doxorubicin and streptozocin in the treatment of pancreatic NETs.
However in that series chemotherapy was continued for up to
15.5 months and the authors argued that late response was a
justification to continue chemotherapy until progression. In
contrast our study data suggest that delayed response occurs even
in the absence of ongoing chemotherapy and reflects the distinct
biology of these tumours. This finding underlines the importance
of longer-term follow-up imaging to define response accurately.
The FCiSt regimen was generally well tolerated. In contrast
to previous studies, we have used an outpatient, 1 day, three
weekly schedule using 1000mgm
 2 streptozocin rather than the
4–500mgm
 2 5-day regimen, thereby improving patient conve-
nience without compromising efficacy. It is notable that the
combination of two nephrotoxic agents, streptozocin and cisplatin,
used according to our schedule did not cause any grade 3–4 renal
toxicity. Concern about renal toxicity for cisplatin in the field of
NETs was raised by two studies (Moertel et al, 1991; Fjallskog et al,
2001) in which cisplatin was administered as a continuous infusion
45mgm
 2 per day for 2 days. Some patients in these studies had
Table 3 Response and predictive markers
Response
Predictor
(normal
range) PR SD PD
PR
(%)
Fisher’s
exact test
P-value
v
2-test
for trend
P-value
All (n¼79) 26 40 13 33
Primary
Pancreas 18 24 5 38 0.24
* —
Non-pancreas 8 16 8 25 —
Unknown 3 7 4 21
Lung 2 4 2 25
GI tract 2 5 2 22
Ovarian 1 0 0 100
Octreotide
Positive 19 32 5 34 0.99 —
Negative 6 5 7 33 —
5HIAA
Positive 2 6 2 20 0.99 —
Negative 10 19 7 28 —
AFP (0–11.3ngml
 1)
p16 10 22 8 25 0.020 —
416 9 5 0 64
HCG (0–2.5mIUml
 1)
p4 10 16 5 32 0.48 —
44 5 5 1 46 —
CA19.9 (0–39Uml
 1)
p40 7 17 5 24 0.23 —
440 10 10 3 43
Chromogranin A (0–60Ul
 1)
p60 6 12 1 32 0.99
460 9 13 3 36
Ki-67 (%)
p9 4 15 3 18 0.059 0.019
10–24 9 13 2 38
X25 12 6 5 52
Mitosis per 10 HPF
0–1 3 14 3 15 0.032 0.008
2–4 7 13 4 29
X51 1 5 4 5 5
WHO grade
1 1 4 2 14 0.085 0.023
21 5 2 5 6 3 3
39 3 3 6 0
PS
0–1 22 36 10 32 0.99
X24 4 3 3 6
Age
p60 20 27 10 35 0.60
460 6 13 3 27
Differentiation
Well 15 30 9 26 0.046
Poorly 10 4 4 56
Abbreviations: GI¼gastrointestinal; 5HIAA¼5-hydroxyindoleacetic acid;
HCG¼human chorionic gonadotropin; HPF¼high-power field; PD¼progressive
disease; PR¼partial response; PS¼performance status; SD¼stable disease;
WHO¼World Health Organization. *Comparing pancreatic vs non-pancreatic.
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salready received high-dose streptozocin and had documented renal
impairment. By contrast our patients were chemonaive and were
required to have a baseline GFR above 60mlmin
 1 as outlined in
the methods. Similar to the study by Mitry et al (1999), who
reported minimal renal toxicity for a 2h infusion of cisplatin at
a dose of 100mgm
 2, we experience minimal toxicity using
a short infusion at 70mgm
 2.
The prognostic factors associated with survival in patients
with NETs have been well defined and include grade, stage,
primary site, sex, age and race (Yao et al, 2008) and, in patients
treated with chemotherapy, the extent of liver metastasis
(Kouvaraki et al, 2004). In our selected cohort of patients CGA
was found to be prognostic for OS and there was evidence to
suggest that Ki-67 index and MI may also be prognostic but in this
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01 2 24 36 48 60
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Figure 1 Overall survival (A) and progression-free survival (B). Overall survival according to differentiation status (C), normal or elevated serum
chromogranin A (D) mitotic index (MI) (E) Ki-67 index (F).
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Unusually, patients with a pancreatic primary tumour had a
better survival than those with a non-pancreatic primary tumour.
The likely explanation for this observation is that in our series,
selected for chemotherapy, 30% of patients with non-pancreatic
primary tumour had high-grade tumours whereas for patients
with pancreatic primary tumour the proportion was only 10%
and grade was a dominant prognostic factor (Pape
et al, 2008b; Yao et al, 2008).
Less well defined in the literature are the factors that predict
response to chemotherapy. Assessment of the proliferation fraction as
measured by MIB1 staining of Ki-67 410% has been proposed as a
means of selecting patients for cytotoxic treatment but it is acknowl-
edged that clear evidence for this strategy is lacking (Vilar et al,2 0 0 7 ) .
We have used our large, homogeneously treated, consecutive series to
examine for predictors of response. In our analysis there was a trend
f o rr e s p o n s er a t et oi n c r e a s ew i t hah i g h e rK i - 6 7i n d e xb u te v e ni n
those with Ki-67p9 %t h er e s p o n s er a t ew a s1 8 % .H e n c ei fK i - 6 7i st o
be used to select patients for chemotherapy the cut off remains to be
defined but our study data suggest that it should be less than 10%.
MI and tumour grade were good predictors of response with higher-
grade tumours and those with a high mitotic rate having a higher
response rate. To the best of our knowledge this is the first systematic
analysis of MI and Ki-67 index as predictors of response and
prognosis for NETs in patients treated with chemotherapy.
We have previously reported that elevations of AFP and b-HCG
(41.5 ULN) are associated with a poorer survival in NETs (Shah
et al, 2008). In contrast neither of these markers was prognostic in
the current cohort treated with chemotherapy. Intriguingly an
elevated AFP may be associated with a higher response rate and one
can speculate that treating these patients with chemotherapy
improves their survival such that the prognostic value of the baseline
measurement is obscured. Neither serum CGA, nor urinary 5HIAA
nor somatostatin receptor expression had any predictive value.
Importantly, we were unable to identify a group of patients who did
not respond to chemotherapy. In this series, 14% (1 out of 7) of the
few patients with low-grade tumours responded to chemotherapy, and
1 5 %( 3o u to f2 0 )o ft u m o u r sw i t ha nM Io fo2( l o w - g r a d eM I )
responded, challenging the view that these tumours are resistant to
chemotherapy. However, there are a number of factors that should be
considered in interpreting this data. Potentially this finding may
reflect tumour heterogeneity not captured by percutaneous biopsy,
with the response in ‘low-grade’ tumours reflecting unsampled higher-
grade tumour that responds to chemotherapy. It is also possible that
histologically low-grade tumours at diagnosis have become higher-
grade tumours by the time treatment is initiated. Finally, the late
responding nature of many low/intermediate-grade tumours, which
we have identified in this study, suggests that chemosensitivity of
these tumours may have previously been underestimated.
Non-streptozocin-based chemotherapy regimens have been
explored in NETs and while agents such as paclitaxel (Ansell
et al, 2001) and gemcitabine (Kulke et al, 2004) appear to be
ineffective, there are encouraging data for temozolamide in
uncontrolled phase II trials (Kulke et al, 2006; Ekeblad et al,
2007). A significant difficulty in comparing reports for different
chemotherapy regimens in NETs relates to heterogeneity of this
patient population. Survival times can be as short as 5 months for
poorly differentiated metastatic tumours or as long as 223 months
for those with localised well-differentiated tumours (Yao et al,
2008). Here we have shown the predictive value of grade, MI and
AFP, and the prognostic importance of Ki-67, MI and CGA in a
cohort of patients treated, first line, with a single chemotherapy
regimen. Accurate reporting of patient and tumour characteristics
is therefore essential but randomised trials are also required to
define the optimal regimen. In the UK, the most widely used
combination chemotherapy for NETs is streptozocin and a
fluoropyramidine (SF) and, on the basis of the data presented
here, the UKCRN is currently recruiting to a randomised phase II
trial of SF with/without cisplatin.
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Table 4 Univariable analysis for prognostic indicators
Risk factor
PFS HR
(99% CI) P-value
OS HR
(99% CI) P-value
Age (for an increase
of 10 years)
1.05 (0.80– 1.39) 0.63 1.15 (0.84–1.59) 0.24
Grade
1 1.00 0.39 1.00 0.03
2 0.73 (0.27–1.99) 0.45 (0.15–1.36)
3 1.09 (0.34–3.44) 1.03 (0.30–3.52)
PS
0–1 1.00 0.33 1.00 0.038
41 1.40 (0.59–3.28) 2.32 (0.89–6.05)
Primary site
Non-pancreatic 1.00 0.18 1.00 0.03
Pancreatic 0.72 (0.38–1.35) 0.54 (0.26–1.11)
Differentiation
Well 1.00 0.44 1.00 0.016
Poorly 1.26 (0.60–2.67) 2.16 (0.99–4.71)
Abbreviations: HR¼hazard ratio; OS¼overall survival; PFS¼progression-free
survival; PS¼performance status.
Table 5 Multivariable analysis for prognostic markers
Marker
PFS HR
(99% CI) P-value
OS HR
(99%CI) P-value
AFP (n¼57)
p16ngml
 1 1.00 0.49 1.00 0.58
416ngml
 1 1.30 (0.50–3.42) 1.25 (0.45–3.52)
HCG (n¼45)
p4mIUml
 1 1.00 0.17 1.00 0.15
44mIUml
 1 0.72 (0.21–2.45) 2.35 (0.54–10.21)
CA19.9 (n¼55)
p40 1.00 0.06 1.00 0.60
440 0.49 (0.18–1.35) 0.81 (0.28–2.33)
Chromogranin A (n¼46)
p60Ul
 1 1.00 0.017 1.00 o0.001
460Ul
 1 2.77 (0.88–8.66) 6.77 (1.26–36.50)
Ki-67 % (n¼72)*
o9 1.00 0.38 1.00 0.017
10–24 1.06 (0.43–2.59) 1.18 (0.39–3.55)
X25 1.51 (0.65–3.51) 2.59 (0.98–6.83)
Mitosis per 10 HPF (n¼66)*
0–1 1.00 0.04 1.00 0.017
2–4 1.04 (0.43–2.51) 1.29 (0.49–3.36)
X5 2.29 (0.91–5.78) 2.99 (1.07–8.36)
Abbreviations: AFP¼a-fetoprotein; HCG¼human chorionic gonadotropin;
HPF¼high-power field; HR¼hazard ratio; OS¼overall survival; PFS¼progression-
free survival. Hazard ratios adjusted for age, grade, primary site and performance
status. *Adjusted for performance status, primary site and age.
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